Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline Maintenance Therapy for Smoking Cessation
2024-518936-36-00Phase 4Authorised
- Sponsor
- Idis
- Start
- May 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cytisinicline in nicotine dependence (2 arms), sponsored by Idis. Primary endpoints: Point and continuous smoking abstinence at 3, 6, and 12 months and Safety: incidence of adverse effects. Planned start May 2025; status: authorised.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2024-518936-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518936-36-00.